Hematopoietic progenitor kinase 1 (HPK1), a critical negative regulator of T cell receptor (TCR) signaling, has emerged as a promising druggable target for T cell-based cancer immunotherapy. In recent years, significant progress has been made in the development of small-molecule inhibitors and proteolysis-targeting chimeras (PROTACs) targeting HPK1. This review summarizes the latest advances in small-molecule drug discovery targeting HPK1 from a medicinal chemistry perspective, discusses diverse strategies for developing novel HPK1 therapeutics, and concludes with an outlook on future directions and challenges in this field. • Targeting intracellular TCR signaling regulators to enhance/rejuvenate T-cell tumor killing is key focus in T-cell immunotherapy. • HPK1, a critical negative regulator of TCR signaling, is a promising druggable target for T-cell cancer immunotherapy. • We summarize recent advances in HPK1-targeted drug development, including inhibitors and PROTACs. • Overcoming bell-shaped cytokine response and improving monotherapy efficacy are key challenges for HPK1-targeted therapeutics.